Top

Published in:

01-06-2005 | Poster Presentation

Large-scale single nucleotide polymorphism analysis of candidates for low-penetrance breast cancer genes

Authors: A Vega, A Salas, C Phillips, B Sobrino, B Carracedo, C Ruíz-Ponte, R Rodríguez-López, G Rivas, J Benítez, A Carracedo

Published in: Breast Cancer Research | Special Issue 2/2005

Excerpt

BRCA1 and BRCA2 are high-penetrance genes that account for around 25% of families with hereditary breast cancer [1]. Given that no additional high-penetrance susceptibility genes have been found to be involved in breast cancer, it has been proposed that different genetic backgrounds due to the combination of low-penetrance genes (polygenic mechanism) could explain the remaining familial breast cancer risk [2]. Hence there is much interest in the search for low-penetrance gene/variants for breast cancer, which exist with high prevalence in the general population. …

Ford D, Easton DF, Stratton M, Narod S, Goldgar D, Devilee P, Bishop DT, Weber B, Lenoir G, Chang-Claude J, et al: Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. Breast Cancer Linkage Consortium. Am J Hum Genet. 1998, 62: 676-689. 10.1086/301749.CrossRefPubMedPubMedCentral

Pharoah PD, Antoniou A, Bobrow M, Zimmern RL, Easton DF, Ponder BA: Polygenic susceptibility to breast cancer and implications for prevention. Nat Genet. 2002, 31: 33-36. 10.1038/ng853.CrossRefPubMed

Kruglyak L: Prospects for whole-genome linkage disequilibrium mapping of common disease genes. Nat Genet. 1999, 22: 139-144. 10.1038/9642.CrossRefPubMed

Venter JC, Adams MD, Myers EW, Li PW, Mural RJ, Sutton GG, et al: The sequence of the human genome. Science. 2001, 291: 1304-1351. 10.1126/science.1058040.CrossRefPubMed

Title: Large-scale single nucleotide polymorphism analysis of candidates for low-penetrance breast cancer genes
Authors: A Vega
A Salas
C Phillips
B Sobrino
B Carracedo
C Ruíz-Ponte
R Rodríguez-López
G Rivas
J Benítez
A Carracedo
Publication date: 01-06-2005
Publisher: BioMed Central
Published in: Breast Cancer Research / Issue Special Issue 2/2005
Electronic ISSN: 1465-542X
DOI: https://doi.org/10.1186/bcr1101

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

ACC 2024 Congress

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Special Issue 2/2005

Dynamic imaging of plasticity and escape in tumor cell invasion

Discovering genetic profiles by array-CGH in familial breast tumors

The anti-estrogen ICI 182,780, but not tamoxifen, inhibits the growth of MCF7 breast cancer cells refractory to long-term estrogen deprivation through downregulation of ER and IGF signalling

Screening for germline rearrangements in BRCA1 and BRCA2in Norwegian families with breast or breast/ovarian cancer

RNA integrity number: towards standardization of RNA quality assessment for better reproducibility and reliability of gene expression experiments

Prognostic value genotypes and LOH at TP53 codon 72 and TP53mutations in primary breast cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer